Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T22:40:22.885Z.
Calculation as of: 2026-10-06T22:40:22.885Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f621ea2a381ac0066d385c57ed104ff22630177ee14cd635e65ed0429d7856c2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Aclaris Therapeutics, Inc.
Market Cap
$516.76M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$519.25M
Operating Cash Flow Yield
N/A
TTM Avg
536.71%
3Y Avg
536.71%
5Y Avg
536.71%
Market Cap
$524.43M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$505.87M
Operating Cash Flow Yield
0.27%
TTM Avg
0.34%
3Y Avg
0.34%
5Y Avg
0.34%
Market Cap
$504.04M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$529.58M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$503.93M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$502.81M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$531.52M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | $516.76M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $519.25M | N/A | 536.71% | 536.71% | 536.71% |
| Immix Biopharma, Inc. (IMMX)vs › | $524.43M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $505.87M | 0.27% | 0.34% | 0.34% | 0.34% |
| Crescent Biopharma, Inc. (CBIO)vs › | $504.04M | N/A | N/A | N/A | N/A |
| Shattuck Labs, Inc. (STTK)vs › | $529.58M | N/A | N/A | N/A | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $503.93M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $502.81M | N/A | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $531.52M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | 3.68% | 3.98% | 3.57% | 3.57% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
